COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Centers for Medicare & Medicaid Services released Medicare Part B billing codes and payment allowances for reporting and administering single booster doses of the Moderna and Johnson & Johnson COVID-19 vaccines to eligible adults as authorized Oct. 22 by the Food and Drug Administration.
The recorded webinar identifies the value of communication in a team-based setting introducing the evidence-based set of tools.
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response and Food and Drug Administration extended the shelf life for the monoclonal antibody therapy etesevimab, which currently must be administered with bamlanivimab.
Centers for Disease Control and Prevention Director Rochelle Walensky, M.D., recommended a single COVID-19 vaccine booster dose at least six months after completing an initial mRNA COVID-19 vaccine series for certain individuals at risk for severe COVID-19, as proposed by her agency’s Advisory…
The Food and Drug Administration authorized administering a single booster dose of the Moderna and Johnson…
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted unanimously to recommend a single COVID-19 vaccine booster dose at least six months after completing an initial mRNA COVID-19 vaccine series, in the same risk groups for whom CDC recommended a Pfizer…
A mix-and-match vaccine regimen is permissible for international travelers entering the U.S., according to updated Centers for Disease Control and Prevention guidance.
Two doses of the Pfizer vaccine are 93% effective at preventing COVID-19 hospitalization among children aged 12 to 18, according to a study at 19 pediatric hospitals released by the Centers for Disease Control and Prevention.
The Centers for Disease Control and Prevention updated the list of underlying medical conditions that put adults of any age at higher risk for severe COVID-19 based on the latest scientific evidence.
Abbott Molecular Inc. issued a recall for its Alinity m SARS-CoV-2 AMP Kits and Alinity m Resp-4-Plex AMP Kits, distributed between May 13, 2020, and Aug. 31, 2021, for their potential to give false positive results.